Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
-
Cantor Fitzgerald Upgrades Supernus Pharmaceuticals (SUPN) to Overweight
-
Cantor Fitzgerald Reiterates Neutral Rating on Supernus Pharmaceuticals (SUPN)
-
Cantor Fitzgerald Reiterates Neutral Rating on Supernus Pharmaceuticals (SUPN)
-
Cantor Fitzgerald Downgrades Supernus Pharmaceuticals (SUPN) to Neutral
-
Supernus to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference
-
Supernus to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference
-
Supernus Pharmaceuticals (SUPN) PT Raised to $55 at Cantor Fitzgerald
-
Supernus Pharmaceuticals (SUPN) PT Raised to $52 at Cantor Fitzgerald
-
Supernus Pharmaceuticals (SUPN) PT Raised to $49 at Cantor Fitzgerald
-
Supernus Pharmaceuticals (SUPN) PT Raised to $34 at Cantor Fitzgerald Following 1Q Report
-
Cantor Fitzgerald Reiterates Overweight Rating and $31 PT on Supernus Pharma (SUPN) Following Final FDA Approval of Trokendi XR for Migranes
-
Supernus Pharma (SUPN): Trokendi XR Settlement Removes a Minor Overhang - Cantor
-
Cantor Fitzgerald Starts Supernus Pharmaceuticals (SUPN) at Overweight
